Estimation for Heparin Market for 2032 is USD 14.52 Billion; Increasing Prevalence of Cardiovascular Diseases and Lifestyle Changes Boosts Market Growth

The global heparin market size stood at USD 10.21 billion in 2024. The market is predicted to rise from USD 10.62 billion in 2025 to USD 14.52 billion by 2032 at a CAGR of 4.57% from 2025 to 2032. Fortune Business Insights™ presents this information in its report titled, “Heparin Market Size, Share & Industry Analysis, By Product (Unfractionated Heparin (UFH) and Low Molecular Weight Heparin (LMWH)), By Source (Bovine and Porcine), By Application (Deep Vein Thrombosis & Pulmonary Embolism, Atrial Fibrillation, Heart Attacks, Stroke, and Others), By Route of Administration (Intravenous Infusion and Subcutaneous Injection), By End-User (Hospitals & ASCs, Clinics, and Others), and Regional Forecast, 2025-2032”

Heparin can be termed as a class of first-line anticoagulant drugs which is used to prevent blood clotting. It works by inhibiting the activity of blood clotting factor thereby treating clots in several conditions as well as during surgical procedures. The products are infused into injections or intravenous infusions in order to reduce the risk of pulmonary embolism, deep vein thrombosis, or during surgeries. The key players are dedicated to improving the quality of such products to treat cardiovascular diseases and other diseases through strong research and innovation.

Optimvia to Partner with Gingko to Improve Efficiency of Biosynthetic Heparin

In January 2022, a partnership was formed between Optimvia and Gingko Bioworks which is a leading platform for cell programming. The primary reason behind Optimvia agreeing to the partnership is to leverage cell and enzyme engineering platforms of Gingko as well as the fermentation process development of the company. As a result, the company can expertise in improving the manufacturing efficiency of biosynthetic heparin.

Rising Prevalence of Cardiovascular Diseases Boosts Product Demand

The heparin market growth is driven by the rising prevalence of cardiovascular diseases, embolism, and thrombosis. The primary reason behind the rise of such kinds of diseases is lifestyle modification and the rising aging population. Therefore, heparin is a vital lifesaving drug which is often prescribed in certain life-threatening medical conditions. This further boosts the demand of the product in the market in order to reduce the risk of cardiovascular diseases. However, the traditional sources for extracting raw materials have a risk of transmitting zoonotic diseases. So, to avoid such problems the researchers are developing chemoenzymatic and next-generation bioengineered heparin.

However, the market faces certain challenges as the Muslim-community due to religious beliefs does not consume pork-based products, further hampering the adoption of porcine mucosa-based heparin product demand in the population.

Key Players Offer Unfractionated and LMWH Advanced Products in Market to Boost Growth

The market for heparin exhibits a semi-consolidated structure with key players rising the competitive landscape of the industry. The players are actively operating in the global market with a robust product portfolio for finished heparin with advanced product offerings such as LMWH. The companies offer heparin products with safe and effective profiles along with strong, comprehensive, and advanced features. Further, the companies offer LMWH advanced as well as unfractionated products in the market in order to maintain their leading presence globally.

List of the Companies Profiled in the Report

• Opocrin S.p.A. (Italy)
• Baxter (U.S.)
• Pfizer Inc. (U.S.)
• Bioiberica S.A.U. (Spain)
• Fresenius SE & Co. KGaA (Germany)
• Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (China)
• Braun SE (Germany)
• Reddy’s Laboratories Ltd. (India)
• LEO Pharma A/S (Denmark)
• Aspen Holdings (South Africa)
• Sanofi (France)

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/heparin-market-104447

Notable Industry Development

• July 2025: The U.S. company named B. Braun SE launched Heparin Sodium Injections into the market of U.S. It primarily included 25,000 units of Heparin in 0.45% Sodium Chloride Injection (50 units/ml) and 25,000 units of heparin in 0.45% Sodium Chloride Injection (100 units/ml).

Further Report Findings

• In the geographical forefront, North America holds a dominating heparin market share due to factors such as increased prevalence of heart attacks and stroke. The growth is also due to the rising adoption of porcine-based heparin.
• Europe is experiencing notable growth and holds the second-position in the market owing to increasing demand and prevalence of heparin in the region. Countries such as the U.K., France, and Germany are expected to hold the highest share in the region.
• On the basis of product, the low-molecular weight segment holds the highest position in the market due to advantages of low molecular weight heparin (LMWH). As it includes a predictable anticoagulant response, better safety features, and availability of subcutaneous administration.
• Based on application, the heart attack segment held the dominant share in the market due to lifestyle changes, rising geriatric population, and sedentary lifestyles. This increases the demand for the product in the market.

Table of Segmentation